Last Updated : July 24, 2024
Details
Generic Name:
dabrafenib and trametinib
Project Status:
Not filed
Therapeutic Area:
Pediatric low-grade glioma with BRAF V600E
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Tafinlar and Mekinist
Project Line:
Reimbursement Review
Project Number:
NS0029-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
For the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.
Recommendation Type:
Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : July 24, 2024